|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention of vertical transmission of hepatitis B virus infection显示文摘Hepatitis B virus(HBV)is the leading cause of chronic viral hepatitis.Annually,almost two million children younger than 5 years acquire the infection,mostly through vertical or horizontal transmission in early life.Vertical transmission of HBV is a high efficacy phenomenon ranging,in the absence of any preventive interventions,from 70%to 90%for hepatitis e antigen positive mothers and from 10%to 40%for hepatitis e antigen-negative mothers.Maternal viraemia is a preeminent risk factor for vertical transmission of HBV.Maternal screening is the first step to prevent vertical transmission of HBV.Hepatitis B passive and active immunoprophylaxis at birth together with antiviral treatment of highly viraemic mothers are the key strategies for global elimination of HBV infection.Strategies are needed to promote implementation of birth-dose vaccination and hepatitis B immunoglobulins in low-and middle-income countries where the prevalence of the infection is at the highest. | Piero Veronese Icilio Dodi Susanna Esposito Giuseppe Indolfi | 2021 | World Journal of Gastroenterology2021，27，26： | 10 |
| 2 | Kounis syndrome:a clinical entity penetrating from pediatrics to geriatrics显示文摘1 Introduction Kounis syndrome constitutes a coronary hypersensitivity disorder defined by the association of an anaphylactoid,anaphylactic,allergic or hypersensitivity reaction with an acute coronary syndrome,in a physiopathological context involving various interrelated and interacting inflammatory cells,such as mast-cells,eosinophils and platelets.[1,2]Similar entities to Kounis syndrome might involve cerebral and mesenteric arteries. | Mattia Giovannini Ioanna Koniari Francesca Mori Silvia Ricci Luciano De Simone Silvia Favilli Sandra Trapani Giuseppe Indolfi Nicholas George Kounis Elio Novembre | 2020 | Journal of Geriatric Cardiology2020，17，5： | 7 |
| 3 | Adenomyomatosis of the gallbladder in childhood: A systematic review of the literature and an additional case report显示文摘AIM: To investigate the diagnostic and therapeutic assessment in children with adenomyomatosis of the gallbladder(AMG).METHODS: AMG is a degenerative disease characterized by a proliferation of the mucosal epithelium which deeply invaginates and extends into the thickened muscular layer of the gallbladder, causing intramural diverticula. Although AMG is found in up to 5% of cholecystectomy specimens in adult populations, this condition in childhood is extremely uncommon. Authors provide a detailed systematic review of the pediatric literature according to PRISMA guidelines, focusing on diagnostic and therapeutic assessment. An additional case of AMG is also presented. RESULTS:Five studies were finally enclosed, encompassing 5 children with AMG. Analysis was extended to our additional 11-year-old patient, who presented diffuse AMG and pancreatic acinar metaplasia of the gallbladder mucosa and was successfully managed with laparoscopic cholecystectomy. Mean age at presentation was 7.2 years. Unspecific abdominal pain was the commonest symptom. Abdominal ultrasound was performed on all patients, with a diagnostic accuracy of 100%. Five patients underwent cholecystectomy, and at follow-up were asymptomatic. In the remaining patient, completely asymptomatic at diagnosis, a conservative approach with monthly monitoring via ultrasonography was undertaken. CONCLUSION: Considering the remote but possible degeneration leading to cancer and the feasibility of laparoscopic cholecystectomy even in small children, evidence suggests that elective laparoscopic cholecystectomy represent the treatment of choice. Preoperative evaluation of the extrahepatic biliary tree anatomy with cholangio-MRI is strongly recommended. | Filippo Parolini Giuseppe Indolfi Miguel Garcia Magne Marianna Salemme Maurizio Cheli Giovanni Boroni Daniele Alberti | 2016 | World Journal of Clinical Pediatrics2016，5，2： | 6 |
| 4 | Treatment of hepatitis B virus infection in children and adolescents显示文摘Hepatitis B virus(HBV)infection is one of the main causes of morbidity and mortality worldwide.Most children acquire the infection perinatally or during early childhood and develop a chronic hepatitis characterized by a high viral replication and a low-inflammation phase of infection,with normal or only slightly raised aminotransferases.Although a conservative approach in children is usually recommended,different therapies exist and different therapeutic approaches are possible.The main goals of antiviral treatment for children with chronic HBV infection are to suppress viral replication and to warn the disease progression to cirrhosis and hepatocellular carcinoma,although these complications are rare in children.Both United States Food and Drug Administration(USFDA)and European Medicines Agency(EMA)have approved interferon alfa-2b for children aged 1 year and older,pegylated interferon alfa-2a and lamivudine for children aged 3 years and older,entecavir for use in children aged 2 years and older,and adefovir for use in those 12 years of age and older.Tenofovir disoproxil fumarate is approved by EMA for children aged 2 years and older and by USFDA for treatment in children aged 12 years and older.Finally,EMA has approved the use of tenofovir alafenamide for treatment of children aged 12 years and older or for children weighing more than 35 kg independent of age.This narrative review will provide the framework for summarizing indications to antiviral therapy in the management of chronic HBV infection in children and adolescents. | Mariangela Stinco Chiara Rubino Sandra Trapani Giuseppe Indolfi | 2021 | World Journal of Gastroenterology2021，27，36： | 5 |
| 5 | New treatments for chronic hepatitis C:an overview for paediatricians显示文摘Pegylated interferon(IFN)α-2a or 2b in combination with ribavirin for children aged 3 years and older is the standard treatment for paediatric chronic hepatitis C.This treatment regimen was developed firstly in adults.In recent years,a number of direct-acting antiviral agents(DAAs)are under development for treatment of chronic hepatitis C virus(HCV)infection.These agents block viral replication inhibiting directly one of the several steps of HCV lifecycle.DAAs are classified into several categories based on their molecular target:HCV NS3/4A protease inhibitors,HCV NS5B polymerase inhibitors and HCV NS5A inhibitors.Other promising compounds are cyclophilin A inhibitors,mi-RNA122and IFN-λ.Several new drugs associations will be developed in the near future starting from the actual standard of care.IFN-based and IFN-free regimens are being studied in adults.In this constantly evolving scenario new drug regimens targeted and suitable for children would be possible in the next future.Especially for children,it is crucial to identify the right combination of drugs with the highest potency,barrier toresistance and the best safety profile. | Daniele Serranti Giuseppe Indolfi Massimo Resti | 2014 | World Journal of Gastroenterology2014，20，43： | 2 |
| 6 | Perinatal Transmission of Hepatitis C Virus显示文摘 | Giuseppe Indolfi Chiara Azzari Massimo Resti | 2013 | The Journal of Pediatrics2013，，： | 1 |
| 7 | Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture 显示文摘 | INDOLFI C TORELLA D COPPOLA C | 2002 | Am J Physiol Heart Circ Physiol2002，283，2： | 1 |
| 8 | Increased Vascular Endothelial Growth Factor Expression But Impaired Vascular Endothelial Growth Factor Receptor Signaling in the Myocardium of Type 2 Diabetic Patients With Chronic Coronary Heart Disease显示文摘 | Ferdinando Carlo Sasso Daniele Torella Ornella Carbonara Georgina M. Ellison Michele Torella Michelangelo Scardone Claudio Marra Rodolfo Nasti Raffaele Marfella Domenico Cozzolino Ciro Indolfi Maurizio Cotrufo Roberto Torella Teresa Salvatore | 2005 | Journal of the American College of Cardiology2005，，5： | 1 |
| 9 | Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevent cardiac hypertrophy induced by pressure overload and inhibits p21 ras activation显示文摘 | Indolfi C Di Lorenzo E Perrino C | | 0，，： | 1 |
| 10 | Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation显示文摘 | Indolfi C Di Lorenzo E Perrino C | 2002 | Circulation2002，106，16： | 1 |
| 11 | Cardiac stem cell-based myocardial regeneration: towards a translational approach 显示文摘 | Torella D Indolfi C Goldspink DF | 2008 | Car- diovasc Hematol Agents Med Chem2008，6，1： | 1 |
| 12 | Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stentsl Trends 显示文摘 | Indolfi C Mongiardo A Curcio A | 2003 | Cardiovasc Med2003，13，： | 1 |
| 13 | Mechanisms of smooth muscle cell pro- liferation and endothelial regeneration after vascular injury and stent- ing : approach to therapy 显示文摘 | Curcio A Torella D Indolfi C | | Circ J0，75，6： | 1 |
| 14 | Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting:approach to therapy显示文摘 | CURCIO A TORELLA D INDOLFI C | 2011 | Circ J2011，75，： | 1 |
| 15 | Hydroxymethylglutary coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation 显示文摘 | Indolfi C Di Lorenzo E Perrino C | 2002 | Circulation2002，106，16： | 1 |
| 16 | Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation显示文摘 | Indolfi C Di Lorenzo E Perrino C | 2002 | Circulation2002，106，16： | 1 |
| 17 | Aortic and left ventricular remodeling in patients with bicuspid aortic valve without significant valvular dysfunction: A prospective study显示文摘 | Giuseppe Santarpia Giancarlo Scognamiglio Giovanni Di Salvo Michele D’Alto Berardo Sarubbi Emanuele Romeo Ciro Indolfi Maurizio Cotrufo Raffaele Calabrò | 2011 | International Journal of Cardiology2011，，3： | 1 |
| 18 | Recent advances in the pre- vention of anthracycline card-iotoxicity in childhood显示文摘 | Iarussi D Indolfi P Casale F etal | 2001 | Curr Med Chem2001，8，13： | 1 |
| 19 | Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents 显示文摘 | Indolfi C Mongiardo A Curcio A | 2003 | Trends Cardiovasc Med2003，4，13： | 1 |
| 20 | The role of heart rate in myocardial ischemia and infarction:Implications of myocardial perfusion-contraction matching显示文摘 | Indolfi C Ross J Jr | 1993 | prog Cardiovasc Dis1993，36，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员